Sign In
Buy IMV
$0.82
+0 (+0%)
At Close: Jul 27, 2023
VANCOUVER, BC , Feb. 21, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce has completed the acquisition of the enti
VANCOUVER, BC , Feb. 12, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive Asset Purchase A
IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process
07:05am, Wednesday, 26'th Jul 2023
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (the “Company” or “IMV”), recently announced an update on the Sales and Investment Solicitation Process (the “SISP”) implemented as part o
IMV Receives NASDAQ Delisting Notice
04:30pm, Monday, 08'th May 2023
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (the “Company” or “IMV”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immu
Horizon Technology Finance Announces First Quarter 2023 Financial Results
04:15pm, Tuesday, 02'nd May 2023
- First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform E
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives
12:30pm, Monday, 01'st May 2023
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (the “Company” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company develo
Sudan: Evacuate stranded Nigerians now – Ibadan indigenes appeal to Buhari
02:48pm, Monday, 24'th Apr 2023
A group of indigenes of Ibadan, the Oyo State capital, under the auspices of Ibadan Mega Voice (IMV) has enjoined the Federal Government not to waste time in evacuating stranded Nigerians in Sudan. Th
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
04:15pm, Friday, 31'st Mar 2023
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio o
IMV Inc. Announces Changes to Its Board of Directors
04:15pm, Monday, 27'th Mar 2023
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, bas
IMV Inc. (IMV) Q4 2022 Earnings Call Transcript
11:02am, Thursday, 16'th Mar 2023
IMV Inc. (NASDAQ:IMV ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Andrew Hall - Chief Executive Officer Brittany Davison - Chief Accounting Officer Jeremy Graff -
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results
07:05am, Thursday, 16'th Mar 2023
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio o
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
07:05am, Thursday, 09'th Mar 2023
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, bas
Do not disappoint the electorate – Ibadan indigenes tell senator, reps-elect
02:42pm, Sunday, 05'th Mar 2023
Ibadan Mega Voice (IMV), a group of Ibadan indigenes who are practitioners have enjoined winners of last Saturday’s national assembly election not to disappoint the electorate. The group also enjoin
IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
07:05am, Monday, 13'th Feb 2023
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc.
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S
05:00pm, Sunday, 08'th Jan 2023
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--( BUSINESS WIRE )--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of i
